These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25012568)

  • 1. Synthesis and biological evaluation of 2-anilino-4-substituted-7H-pyrrolopyrimidines as PDK1 inhibitors.
    O'Brien NJ; Brzozowski M; Buskes MJ; Deady LW; Abbott BM
    Bioorg Med Chem; 2014 Aug; 22(15):3879-86. PubMed ID: 25012568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of substituted 3-anilino-quinolin-2(1H)-ones as PDK1 inhibitors.
    O'Brien NJ; Brzozowski M; Wilson DJ; Deady LW; Abbott BM
    Bioorg Med Chem; 2014 Jul; 22(14):3781-90. PubMed ID: 24856302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads.
    Bursavich MG; Dastrup D; Shenderovich M; Yager KM; Cimbora DM; Williams B; Kumar DV
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6829-33. PubMed ID: 24183538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
    Le Brazidec JY; Pasis A; Tam B; Boykin C; Wang D; Marcotte DJ; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4033-7. PubMed ID: 22607669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
    Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
    Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent Pyrimidine and Pyrrolopyrimidine Inhibitors of Testis-Specific Serine/Threonine Kinase 2 (TSSK2).
    Hawkinson JE; Sinville R; Mudaliar D; Shetty J; Ward T; Herr JC; Georg GI
    ChemMedChem; 2017 Nov; 12(22):1857-1865. PubMed ID: 28952188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
    Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of novel 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases.
    Deau E; Loidreau Y; Marchand P; Nourrisson MR; Loaëc N; Meijer L; Levacher V; Besson T
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6784-8. PubMed ID: 24176400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of pyrrolopyrimidine inhibitors of Akt.
    Blake JF; Kallan NC; Xiao D; Xu R; Bencsik JR; Skelton NJ; Spencer KL; Mitchell IS; Woessner RD; Gloor SL; Risom T; Gross SD; Martinson M; Morales TH; Vigers GP; Brandhuber BJ
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5607-12. PubMed ID: 20810279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent synthesis of kinase inhibitor derivatives, leading to discovery of selective Gck inhibitors.
    Matsumaru T; Inai M; Ishigami K; Iwamatsu T; Maita H; Otsuguro S; Nomura T; Matsuda A; Ichikawa S; Sakaitani M; Shuto S; Maenaka K; Kan T
    Bioorg Med Chem Lett; 2017 May; 27(10):2144-2147. PubMed ID: 28385506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
    McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.
    Kaspersen SJ; Sørum C; Willassen V; Fuglseth E; Kjøbli E; Bjørkøy G; Sundby E; Hoff BH
    Eur J Med Chem; 2011 Dec; 46(12):6002-14. PubMed ID: 22018877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, crystal structures and anticancer activity of 4-substituted quinolines to target PDK1.
    Vennila KN; Sunny D; Madhuri S; Ciattini S; Chelazzi L; Elango KP
    Bioorg Chem; 2018 Dec; 81():184-190. PubMed ID: 30138906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X-ray Crystal Structure-Guided Design and Optimization of 7
    Lee Y; Kim H; Kim H; Cho HY; Jee JG; Seo KA; Son JB; Ko E; Choi HG; Kim ND; Kim I
    J Med Chem; 2021 May; 64(10):6985-6995. PubMed ID: 33942608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).
    Murphy ST; Alton G; Bailey S; Baxi SM; Burke BJ; Chappie TA; Ermolieff J; Ferre R; Greasley S; Hickey M; Humphrey J; Kablaoui N; Kath J; Kazmirski S; Kraus M; Kupchinsky S; Li J; Lingardo L; Marx MA; Richter D; Tanis SP; Tran K; Vernier W; Xie Z; Yin MJ; Yu XH
    J Med Chem; 2011 Dec; 54(24):8490-500. PubMed ID: 22040023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.
    Pathania S; Rawal RK
    Eur J Med Chem; 2018 Sep; 157():503-526. PubMed ID: 30114661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
    Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
    J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinases.
    McIver EG; Bryans J; Birchall K; Chugh J; Drake T; Lewis SJ; Osborne J; Smiljanic-Hurley E; Tsang W; Kamal A; Levy A; Newman M; Taylor D; Arthur JS; Clark K; Cohen P
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7169-73. PubMed ID: 23099093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of benzoazepin-2-one analogs as allosteric binders targeting the PIF pocket of PDK1.
    Wei L; Gao X; Warne R; Hao X; Bussiere D; Gu XJ; Uno T; Liu Y
    Bioorg Med Chem Lett; 2010 Jul; 20(13):3897-902. PubMed ID: 20627557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
    Liu Y; Yin Y; Zhang J; Nomie K; Zhang L; Yang D; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2016 May; 349(5):356-62. PubMed ID: 26991997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.